VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

B. pseudomallei DNA vaccine encoding Flagellin Protein B. pseudomallei Subunit LolC Protein Vaccine B. pseudomallei Subunit PotF Protein Vaccine Burkholderia pseudomallei aroC deletion mutant vaccine Burkholderia pseudomallei asd mutant vaccine Burkholderia pseudomallei purM mutant vaccine Burkholderia pseudomallei purN mutant vaccine
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0011538
  • Type: DNA vaccine
  • Status: Research
  • fliC gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Vector: pcDNA3 (Chen et al., 2006)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0011436
  • Type: Subunit vaccine
  • Status: Research
  • LolC/E gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0011438
  • Type: Subunit vaccine
  • Status: Research
  • PotF gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0002825
  • Type: Live, attenuated vaccine
  • Status: Research
  • aroC gene engineering:
    • Type: Gene mutation
    • Detailed Gene Information: Click Here.
  • Preparation: An unmarked aroC deletion mutant of B. pseudomallei strain A2 was constructed using a sucrose counter-selection strategy. The aroC deletion in the resultant mutant, designated A2DeltaaroC, was confirmed by PCR, Southern hybridization and failure of the mutant to grow in a defined medium without aromatic compound (Srilunchang et al., 2009).
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0002826
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • asd gene engineering:
    • Type: Gene mutation
    • Description: This asd mutant is from Burkholderia pseudomallei (Norris et al., 2011).
    • Detailed Gene Information: Click Here.
  • Immunization Route: intranasal immunization
  • Vaccine Ontology ID: VO_0002827
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • purM gene engineering:
    • Type: Gene mutation
    • Description: This purM mutant is from Burkholderia pseudomallei (Breitbach et al., 2008).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0002828
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • purN gene engineering:
    • Type: Gene mutation
    • Description: This purN mutant is from Burkholderia pseudomallei (Breitbach et al., 2008).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intraperitoneal injection (i.p.)
Host Response Host Response Host Response Host Response Host Response Host Response Host Response

Mouse Response

  • Host Strain: Balb/c
  • Vaccination Protocol: Six-week-old female Balb/c mice from groups 1–3 were injected intramuscularly (i.m.) with pcDNA3/fliC in PBS (50, 100 or 150 μg); whereas those from group 4 (the negative control) were injected (i.m) with vector DNA(150 μg; pcDNA3) in PBS, whilst those from group 5 (the positive control) were injected subcutaneously with recombinant flagellin antigens (50 μg) emulsified in complete Freund's adjuvant. Each animal from group 5 was subsequently boosted with the same dose of flagellin in incomplete Freund's adjuvant 14 days subsequent to the initial flagellin injection. The animals in groups 1–4 were boosted twice with an identical dose of plasmid DNA, once at 7 days and then again at 14 days after the initial injection (Chen et al., 2006).
  • Challenge Protocol: The immunized mice were infected via the tail vein with 105 CFU of mixed B. pseudomallei suspended in sterile PBS (50 μl). As control groups, the mice received either sterile PBS or vector DNA (Chen et al., 2006).
  • Efficacy: Subsequent intravenous challenge of the vaccinated Balb/c mice with 10(5)CFU of B. pseudomallei resulted in the number of bacterial cells detected in liver and/or spleen being significantly reduced in the flagellin plasmid DNA vaccinated mice. At 7 days subsequent to infection of B. pseudomallei, 5/6 (83%) of flagellin plasmid DNA vaccinated mice had survived (Chen et al., 2006).
  • Host Ifng (Interferon gamma) response
    • Description: Mice spleen cells were collected after an eight-week immunization. The up-regulation of IFN-γ production among the mice immunized with pcDNA3/fliC was significantly greater than among the mice either immunized with recombinant flagellin or vaccinated with vector DNA only (Chen et al., 2006).
    • Detailed Gene Information: Click Here.

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Female 5- to 6-week-old BALB/c mice were immunized with the purified recombinant LolC protein given with adjuvant (Harland et al., 2007).
  • Challenge Protocol: Mice immunized with the LolC protein or appropriate controls were challenged with B. pseudomallei K96243 on day 70 (Harland et al., 2007).
  • Efficacy: The recombinant LolC protein afforded significant protection against the B. pseudomallei challenge (Harland et al., 2007).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Female 5- to 6-week-old BALB/c mice were immunized with the purified recombinant PotF protein given with adjuvant (Harland et al., 2007).
  • Challenge Protocol: Mice immunized with the PotF protein or appropriate controls were challenged with B. pseudomallei K96243 on day 70 (Harland et al., 2007).
  • Efficacy: Immunization with the PotF protein domain afforded significant protection against a subsequent challenge with B. pseudomallei (Harland et al., 2007).

Mouse Response

  • Persistence: Compared to the parental wild type strain, A2DeltaaroC was highly attenuated for virulence following intraperitoneal introduction into BALB/c and C57BL/6 mice (Srilunchang et al., 2009).
  • Efficacy: C57BL/6 mice immunized intraperitoneally with A2DeltaaroC were significantly protected against a challenge dose of 6,000 cfu (20 x LD50) (Srilunchang et al., 2009).

Mouse Response

  • Persistence: An asd mutant is highly attenuated in mice (Norris et al., 2011).
  • Efficacy: An asd mutant induces protection against challenge with wild type B. pseudomallei (Norris et al., 2011).

Mouse Response

Mouse Response

  • Persistence: A purN mutant was attenuated in mice, as mice did not show any clinical symptoms of illness (Breitbach et al., 2008).
  • Efficacy: A purN induced strong protection in mice from challenge with wild type B. pseudomallei (Breitbach et al., 2008).
References References References References References References References
Chen et al., 2006: Chen YS, Hsiao YS, Lin HH, Yen CM, Chen SC, Chen YL. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine. 2006; 24(6); 750-758. [PubMed: 16169637].
Harland et al., 2007: Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infection and immunity. 2007; 75(8); 4173-4180. [PubMed: 17517877].
Harland et al., 2007: Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infection and immunity. 2007; 75(8); 4173-4180. [PubMed: 17517877].
Srilunchang et al., 2009: Srilunchang T, Proungvitaya T, Wongratanacheewin S, Strugnell R, Homchampa P. Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2. The Southeast Asian journal of tropical medicine and public health. 2009; 40(1); 123-130. [PubMed: 19323044].
Norris et al., 2011: Norris MH, Propst KL, Kang Y, Dow SW, Schweizer HP, Hoang TT. The Burkholderia pseudomallei {Delta}asd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice. Infection and immunity. 2011; ; . [PubMed: 21807903].
Breitbach et al., 2008: Breitbach K, Köhler J, Steinmetz I. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008; 102 Suppl 1; S89-94. [PubMed: 19121696].
Breitbach et al., 2008: Breitbach K, Köhler J, Steinmetz I. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008; 102 Suppl 1; S89-94. [PubMed: 19121696].